Marburg, 29 November 2023 – On 1 January 2024, Dr Niklas Schier will join the management of CSL Behring GmbH as the third Managing Director alongside Michael Schroeder and Dr Lutz Bonacker and take over the management of the production site in Marburg from Michael Schroeder as his designated successor. As planned, Schroeder will provide his expertise until mid-2024 to ensure the greatest possible continuity in the handover.
In Dr Schier, a leader with a wealth of experience and extensive knowledge of quality and manufacturing processes has been gained as the new site manager. Dr Schier, who holds a doctorate in microbiology, joined CSL Behring in February 2020 as head of the Marburg Quality department. As Vice President of Quality Operations, he assumed global responsibility for the quality and safety of life-saving medicines manufactured at the sites in the global CSL Behring network in September 2021. Since May 2023, he has headed CSL Behring's global Quality organization.
The Philipps University graduate is no stranger to the Behringwerke site. Prior to joining CSL Behring, Dr Schier held various positions in production at Chiron and Novartis before GSK appointed him Site Head of Quality and Managing Director.
"I am very much looking forward to the new tasks and challenges, which I will tackle with a lot of energy together with the great team at the site. With Michael as a strong partner in the initial phase, our team will experience the necessary stability and additional impetus," says Dr Schier.
Michael Schroeder has been with CSL Behring for more than 35 years. He laid the foundation for his professional career with an apprenticeship as a biology laboratory technician at the Behringwerke site. Over the years, he has held many different management positions. In 2019, Schöder took over his position as Site Manager and Managing Director.
"I am very interested in the positive development of our site here in Marburg and I am sure that Niklas will drive this forward together with the great team for our region and, above all, for our patients," says Schroeder.
Dr Lutz Bonacker was also pleased with the continuous transition. He thanked Schroeder for his tireless commitment to the employees and the interests of the Marburg site.
